Tokyo, March 19 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060979) titled 'A Study on the Clinical Features of Metastatic Castration-Resistant Prostate Cancer Using PSMA-PET and FDG-PET' on March 19.
Study Type:
Interventional
Study Design:
Basic Design - Single arm
Randomization - Non-randomized
Blinding - Open -no one is blinded
Control - Uncontrolled
Primary Sponsor:
Institute - The University of Osaka
Condition:
Condition - Metastatic Castration-Resistant Prostate Cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - The aim of this study is to elucidate the tumor characteristics in patients with metastatic castration-resistant prostate cancer undergoing 68Ga-PSMA-PET/CT, using FDG-PET/CT performed concurrently.
Basic objectives2 - Others
Intervention:
Interventions/Control_1 - FDG-PET/CT
Eligibility:
Age-lower limit - 20
years-old
<=
Age-upper limit - Not applicable
Gender - Male
Key inclusion criteria - Patients with metastatic castration-resistant prostate cancer undergoing PSMA-PET/CT imaging to aid in determining eligibility for radioligand therapy
Key exclusion criteria - Individuals who declined to participate in this study
Target Size - 100
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 03 Month 18 Day
Anticipated trial start date - 2026 Year 04 Month 01 Day
Last follow-up date - 2031 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069081
Disclaimer: Curated by HT Syndication.
